OverviewSuggest Edit

OxThera is a biopharmaceutical company with products in late stage clinical development focusing on Primary and Secondary Hyperoxaluria. OxThera’s intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria, and enzymes. Oxabact® holds Orphan Drug designations in Europe and in the US for the treatment of primary hyperoxaluria.
TypePrivate
HQStockholm, SE
Websiteoxthera.com

Latest Updates

Employees (est.) (Oct 2020)27
Revenue (FY, 2015)KR11 M(+26%)
Cybersecurity ratingCMore

Key People/Management at OxThera

Georges Gemayel

Georges Gemayel

Chairman
Matthew Gantz

Matthew Gantz

Chief Executive Officer
Mats-Olof Wallin

Mats-Olof Wallin

Chief Financial Officer
Bastian Dehmel

Bastian Dehmel

Chief Medical Officer
Show more

OxThera Office Locations

OxThera has offices in Stockholm and Knoxville
Stockholm, SE (HQ)
Regeringsgatan 111
Knoxville, US
245 Crowfield Rd
Show all (2)

OxThera Financials and Metrics

Summary Metrics

OxThera total Funding

$53.3 m

OxThera investors

Show all financial metrics

OxThera Revenue

OxThera's revenue was reported to be kr11.01 m in FY, 2015 which is a 25.2% increase from the previous period.
SEK

Revenue (FY, 2015)

11.0m

Revenue growth (FY, 2014 - FY, 2015), %

25.2%

Net income (FY, 2015)

(37.8m)

EBITDA (FY, 2015)

(34.7m)

EBIT (FY, 2015)

(34.8m)

Cash (31-Dec-2015)

8.9m
SEKFY, 2013FY, 2014FY, 2015

Revenue

3.8m8.8m11.0m

Revenue growth, %

131%25%

Sales and marketing expense

64.2m37.8m

General and administrative expense

4.8m7.7m7.8m
SEKY, 2013Y, 2014Y, 2015

Cash

25.3m8.9m

Total Assets

38.6m35.1m15.4m

Total Debt

25.6m53.2m

Total Liabilities

13.0m42.0m57.1m
Show all financial metrics

OxThera Cybersecurity Score

Cybersecurity ratingPremium dataset

C

78/100

SecurityScorecard logo

OxThera Online and Social Media Presence

Embed Graph

OxThera News and Updates

OxThera Announces Completion of Recruitment in Phase 3 ePHex Study With Oxabact® in Patients With Primary Hyperoxaluria

STOCKHOLM, April 6, 2020 /PRNewswire/ -- OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announced today that it has completed enrollment in its Oxabact ePHex phase III study. Oxabact is an investigational...

OxThera Receives Positive Decision From EMA on Paediatric Investigational Plan (PIP) for Treatment of Primary Hyperoxaluria With Oxalobacter formigenes

STOCKHOLM, Sweden, Aug. 23, 2019 /PRNewswire/ -- OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), today announced that, based on a positive opinion from the Paediatric Committee (PDCO), the EMA has agreed to...

Oxthera Presents Continuous Strong Data from an Interim Analysis of Its Phase 2 Study With Oxabact in Primary Hyperoxaluria

STOCKHOLM, June 27, 2019 /PRNewswire/ -- OxThera AB, a privately-held biopharmaceutical company dedicated to improve the lives of people living with Primary Hyperoxaluria (PH), today announced continuous strong data from a two-year interim analysis of its Phase 2 study with Oxabact® in PH....

OxThera Initiates Extension Part of a Phase 3 Study of Oxabact in Primary Hyperoxaluria

STOCKHOLM, June 20, 2019 /PRNewswire/ -- OxThera AB, a biopharmaceutical company dedicated to improve the lives of people living with Primary Hyperoxaluria, today announced that the first patients in a Phase 3 study of Oxabact® have completed the study and transitioned to an open-label...

OxThera AB is Being Granted US Patent for Oxalobacter Secretagogues

STOCKHOLM, November 15, 2018 /PRNewswire/ -- OxThera AB, a privately-held Stockholm-based biopharmaceutical company, today announced a granted US patent on Oxalobacter formigenes secretagogues. Oxabact® , a formulation of highly concentrated lyophilized Oxalobacter formigenes, is being...

OxThera Presents Encouraging 52-Week Efficacy and Safety Data for Oxabact® in Primary Hyperoxaluria Type 1 (PH1) Patients with ESRD

STOCKHOLM, October 31, 2018 /PRNewswire/ -- OxThera AB, a Stockholm-based privately-held biopharmaceutical company and leader in the field of microbiome derived biotherapeutics, today announced a poster presentation showing encouraging Oxabact® efficacy and safety data from the long-term...
Show more

OxThera Blogs

OxThera Frequently Asked Questions

  • Who are OxThera key executives?

    OxThera's key executives are Georges Gemayel, Matthew Gantz and Mats-Olof Wallin.

  • How many employees does OxThera have?

    OxThera has 27 employees.

  • What is OxThera revenue?

    Latest OxThera annual revenue is kr11 m.

  • What is OxThera revenue per employee?

    Latest OxThera revenue per employee is kr407.9 k.

  • Who are OxThera competitors?

    Competitors of OxThera include Qvella, Epic Sciences and Astute Medical.

  • Where is OxThera headquarters?

    OxThera headquarters is located at Regeringsgatan 111, Stockholm.

  • Where are OxThera offices?

    OxThera has offices in Stockholm and Knoxville.

  • How many offices does OxThera have?

    OxThera has 2 offices.